Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals

Title:Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals

Volume: 19 Issue: 12

Author(s): Ceren Hangül, Sibel Berker Karaüzüm , Esra Küpeli Akkol*, Devrim Demir-Dora, Zafer Çetin, Eyüp İlker Saygılı, Gökhan Evcili and Eduardo Sobarzo-Sánchez

Affiliation:

• Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara,Turkey

Keywords: Facioscapulohumeral muscular dystrophy, FSHD, natural compound, phytochemical, nutraceutical, skeletal muscle, dystrophy.

Abstract: Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence. It is not a life-threatening disease; however, the progression of the disease extends over being wheelchair bound. Despite some drug trials continuing, including DUX4 inhibition, TGF-ß inhibition and resokine which promote healthier muscle, there is not an applicable treatment option for FSHD today. Still, there is a need for new agents to heal, stop or at least slow down muscle wasting. Current FSHD studies involving nutraceuticals as vitamin C, vitamin E, coenzyme Q10, zinc, selenium, and phytochemicals as curcumin or genistein, daidzein flavonoids provide promising treatment strategies. In this review, we present the clinical and molecular nature of FSHD and focus on nutraceuticals and phytochemicals that may alleviate FSHD. In the light of the association of impaired pathophysiological FSHD pathways with nutraceuticals and phytochemicals according to the literature, we present both studied and novel approaches that can contribute to FSHD treatment.

Cite this article as:

Hangül Ceren , Karaüzüm Berker Sibel , Akkol Küpeli Esra *, Demir-Dora Devrim , Çetin Zafer , Saygılı İlker Eyüp , Evcili Gökhan and Sobarzo-Sánchez Eduardo , Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals, Current Neuropharmacology 2021; 19 (12) . https://dx.doi.org/10.2174/1570159X19666210726151924